ANZCTR search results

This study will compare two commonly used methods of providing pain relief after robotic gynaecological surgery: a TAP block performed by the surgeon during the operation and a TAP block performed by the anaesthetist using ultrasound guidance. Participants will be randomly assigned to receive one of the two techniques. The main aim is to determine whether the surgeon-performed TAP block provides similar pain relief, measured by the amount of opioid pain medication required in the first 24 hours after surgery. We will also compare pain scores, nausea and vomiting, length of hospital stay, complications, and the time taken to perform each technique. The results may help identify the most effective and efficient approach to pain management for patients undergoing robotic gynaecological surgery.

- This study will test the safety of MAR005 in people with Elevated triglyceride levels. - Up to 10 participants will receive two injections of MAR005, - Participants will attend clinic visits for health checks, study assessments, and monitoring. - The study will also assess how the body responds to and processes MAR005 over time.

- This study will test a new investigational medicine called MAR005 in healthy adult volunteers. - The purpose is to find out whether MAR005 is safe and well tolerated when given multiple times. -Researchers will also study how the body absorbs, distributes, and removes the medicine, and how the medicine affects the body. -Participants will be randomly assigned to receive either MAR005 or a MAR001 and neither the participants nor the study team will know which treatment is being given during the study.

Regional anaesthesia involves using needles to inject a drug close to target nerves. As this carries risks, doctors must obtain verbal and/or written informed consent from patients, meaning they agree while understanding the procedure and associated risks, benefits, and alternatives. However, clinical practise for this skill is often opportunistic, inconsistent, or informal, leading to generative AI-based virtual patients being considered as an emerging teaching technology. This project aims to explore if a generative AI-based virtual patient can be effective in teaching informed consent for regional anaesthesia. First-year trainee anaesthetists will be assessed for consenting skill before and after a 60-minute AI virtual patient training session to determine this.

This study aims to test whether the PAIR Model, a relationship-focused approach to early childhood intervention, can be successfully used in a hospital infant clinic and improve families’ experiences of care. Health professionals at the Queensland Children’s Hospital will be trained to place greater focus on supporting parent–infant relationships during routine therapy sessions. Families receiving PAIR-informed care will be compared with families receiving usual care. The study hypothesises that families receiving PAIR-informed care will report better engagement with therapy and improved goal attainment. Results will inform whether this approach is suitable for wider use in hospital-based early intervention services.

In brief, the REPAIR-W pilot study is designed to examine the effects of single-session memory reconsolidation blockage (i.e., script driven trauma recall administered under propranolol) in women with probable PTSD/TSRD (IES >33), and to determine whether menstrual cycle–related oestradiol variation moderates symptom response. We hope to categorise n=20 naturally cycling women (aged 18-40 years) into "high" (n=10) versus "low" (n=10) oestradiol groups, corresponding to the late versus early follicular phase of the menstrual cycle, respectively. The aim is not to deliver definitive treatment in a single session, but to isolate the role of oestradiol in modulating reconsolidation effects. Symptom change will be assessed one-week, and one-month post-session, with the a priori expectation that (1) measurable symptom reduction will occur, and (2) oestradiol status will influence the magnitude of this effect.

Current treatment strategies for SSc are targeted towards inflammation and pain relief, however they have a modest impact on addressing exertional intolerance, functional disability and their underlying physiology. On the other hand, there is a lack of defined evidence into other preventative non-pharmacological therapeutics such as exercise training in the clinical management of SSc. Due to its multifactorial effects on organ systems, exercise training has been proposed as an ideal adjunct strategy to address functional impairment, symptomatology and/or organ involvement in patients with SSc. However, the efficacy of exercise training in patients with SSc has primarily been explored in small pilot studies with safety-related or patient-reported endpoints. The impact of exercise to alter the physiologic factors that are contributing to symptom burden and morbidity in SSc has not received sufficient attention. Consequently, we want to evaluate whether a goal-directed exercise approach could be efficacious in addressing functional disability.

This project is testing the safety and pharmacokinetics of a single oral dose of a new drug called GBP-088 when given with and without food. GBP-088 is being developed for the treatment of recurrent kidney stones. You may be eligible for this study if you are a healthy adult man or woman aged between 18 and 55 years old. You will receive a single oral dose of active study drug on Day 1 under fasted conditions. After a 4 day washout period you will receive the same oral dose of active study drug given after eating a high fat, high calorie meal. It is hoped that this research will help determine the safety of GBP-088 when given to healthy men or women so that it can be tested in patients with recurrent kidney stone disease

The study aims to evaluate the performance of the Lubdub AECG device compared with a clinically accepted AECG device used in routine clinical care. Participants who are already referred for AECG monitoring will wear both devices at the same time for 24 to 48 hours. The study will assess the technological performance of the Lubdub AECG device during normal daily activities compared to the comparator AECG device. We expect to evaluate if the Lubdub AECG device will provide ECG recordings, signal quality and technological performance comparable to the clinically accepted AECG device, while maintaining high levels of participant usability and comfort.

Opioid overdose is a major public health issue, causing significant morbidity and mortality. Naloxone is a drug for reversal of opioid overdose and is typically administered through intravenous or intramuscular injection. Intranasal administration of naloxone has several advantages over injection, particularly ease of use and removal of the risk of needle stick injury. This study is a randomised controlled trial to test the hypothesis that naloxone administered intranasally will be non-inferior to naloxone administered intramuscularly in achieving an adequate response (no requirement for a rescue dose of intramuscular naloxone). There is limited quality evidence about intranasal naloxone efficacy. Previous trials used volumes greater than the now-recommended optimal delivery volume for intranasal drug administration, of equal to 0.2ml per nostril, or smaller doses than those typically used in the Australian context. Our trial will evaluate the efficacy of a concentrated naloxone spray (2mg/0.1ml) compared to the 800mcg intramuscular standard in reversing the effects of opioid overdose and the production of any naloxone-associated side-effects.